Burosumab

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Burosumab
   1. Pharmacist Assessment Report
   2. Burosumab: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Burosumab: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Burosumab, so there is currently no new predicted indication. The drug’s recorded uses are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	4
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
familial hypophosphatemia	licence in another country
osteomalacia	licence in another country
x-linked dominant hypophosphatemic rickets	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
hereditary hypophosphatemic rickets

Australia Market Information

Licence	Product	Dosage form	Status
13136J	Crysvita	Solution for injection 20 mg in 1 mL	Valid

Safety Considerations

• Contraindications (knowledge graph, not label text): Kidney failure is listed as a contraindication-linked disease. This is directly relevant to the predicted renal indication.
• Drug Interactions (9 identified):
  • Major: calcium phosphate, calcifediol, calcitriol, dihydrotachysterol, doxercalciferol, paricalcitol, sodium cellulose phosphate
  • Moderate: cinacalcet, etelcalcetide

  Many of these are standard therapies in CKD-mineral and bone disorder, so co-prescribing in the target population would be common and needs careful evaluation.

Please refer to the TGA-approved Product Information (PI) for warnings and formal contraindications, as these were not available in the compiled data.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---